Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Graphite Bio, Inc.

Graphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases. The company is pioneering a precision gene editing approach that has the potential to transform human health by achieving one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s UltraHDR™ gene editing platform takes CRISPR beyond cutting and harnesses the power of high-efficiency precision DNA repair, also known as homology-directed repair (HDR), to precisely correct genetic mutations, replace entire disease-causing genes with functional genes or insert new genes into predetermined, safe locations. Additionally, the company is advancing the development of novel conditioning regimens to help bring curative therapies to more patients. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

See our Community Guidelines at bit.ly/3c5Pztz. 

Filer	Shares	Latest Filing Date	Previously owned	Change	Share-Type	Market Value
Vanguard Group Inc	1.38M	2023-08-14	1.23M	145.20K	Shares	3.59M
Deerfield Management Compan...	906.31K	2021-11-15	906.31K	0	Shares	14.85M
Privium Fund Management (Uk...	564.95K	2022-11-01	344.57K	220.38K	Shares	1.79M
Oup Management Co., Llc	406.31K	2023-08-07	406.31K	0	Shares	1.06M
Northern Trust Corp	250.94K	2023-08-11	73.19K	177.75K	Shares	652.44K
Chi Advisors Llc	230.94K	2023-08-22	0	230.94K	Shares	600.44K
Cormorant Asset Management, Lp	199.55K	2023-08-14	199.55K	0	Shares	518.82K
Western Standard Llc	175.08K	2023-08-14	495.39K	-320.31K	Shares	455.22K
Bml Capital Management, Llc	152.29K	2023-07-24	152.29K	0	Shares	395.96K
Aldebaran Capital, Llc	130K	2023-08-09	130K	0	Shares	338K
Cannell Capital Llc	14.31K	2022-11-14	3.95K	10.36K	Shares	45K
K2 Principal Fund, L.P.	0	2023-08-15	969.62K	-969.62K	Shares	0
Apogem Capital Llc	0	2023-02-13	25.33K	-25.33K	Shares	0

NASDAQ:GRPH

Graphite Bio, Inc.

Last Close

3.27

21/03 20:00

Market Cap

185.19M

Beta: -

Volume Today

299.41K

Avg: 209.31K

PE Ratio

−1.24

PFCF: −1.95

Institutional trades

Institutional Ownership

Current holdings institutionals